Detalles de la búsqueda
1.
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.
Lancet HIV
; 11(6): e369-e379, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38734015
2.
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Lancet HIV
; 11(6): e357-e368, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38734016
3.
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
J Acquir Immune Defic Syndr
; 91(1): 68-72, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35972855
4.
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Lancet HIV
; 8(6): e324-e333, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34000227
5.
Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection.
Pharmacotherapy
; 28(1): 90-101, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18154479
6.
Frequency of HIV-related medication errors and associated risk factors in hospitalized patients.
Ann Pharmacother
; 42(4): 491-7, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18349307
7.
Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Pediatr Infect Dis J
; 37(6): e157-e165, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29206748
8.
Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study.
Pediatr Infect Dis J
; 37(6): e149-e156, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29206747
9.
PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years.
J Int AIDS Soc
; 18: 19467, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26066346
10.
Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
J Med Econ
; 16(4): 552-9, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23391157
11.
Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US.
Clinicoecon Outcomes Res
; 5: 437-45, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24039438
12.
Effect of persistency of first-line HIV antiretroviral therapy on clinical outcomes.
AIDS Res Hum Retroviruses
; 29(4): 698-703, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23151191
13.
Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
Expert Opin Pharmacother
; 13(15): 2111-8, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22970926
14.
Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia.
Clin Adv Hematol Oncol
; 3(10): 773-7, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16258487
Resultados
1 -
14
de 14
1
Próxima >
>>